May 29, 2020
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
May 15, 2020
Studies Highlight Key Relationships Between Lifestyle, Sexual Health
May 15, 2020
Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020
May 13, 2020
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model
May 12, 2020
Global Hypogonadism Market Insights, 2016-2024: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares
May 05, 2020
FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial
Apr 17, 2020
U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition
Mar 04, 2020
Lipocine Announces TLANDO(TM) PDUFA Date of August 28, 2020
Feb 27, 2020
Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants
Feb 24, 2020
Lipocine Announces Regulatory Path Forward for TLANDO(TM) Resubmission
Feb 13, 2020
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Feb 11, 2020
Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics
Jan 10, 2020
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Dec 09, 2019
BioTE Medical Founder and Chairman Warns of Potential Serious Impact on Women's Health from Recent Position Statement on Women's Testosterone Therapy Lasting Generations
Nov 18, 2019
Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants
Nov 14, 2019
Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants
Nov 13, 2019
Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution
Nov 13, 2019
Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants
Nov 11, 2019
Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA
Oct 17, 2019
New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months